NEW YORK (GenomeWeb) – Advanced Analytical Technologies (AATI) and Illumina said today that they have entered into a comarketing agreement involving AATI's Fragment Analyzer automated capillary electrophoresis systems for quality control analysis of nucleic acids in Illumina's next-generation sequencing workflows.
AATI's Fragment Analyzer systems provide a scalable method to analyze a broad range of sample types in Illumina NGS library prep workflows, including genomic DNA, RNA, cell-free nucleic acids, single-cell isolates, and sequencing libraries.
"The Fragment Analyzer systems give our customers new options to streamline the analysis of nucleic acid isolates and prepared libraries," Kevin Meldrum, senior director of product marketing at Illumina, said in a statement. "We look forward to working with AATI to provide robust QC solutions, especially as NGS sample numbers grow and multiplexing techniques are empowered by our high-capacity NGS platforms."
AATI noted that Norma Neff, director of genomics at the Chan Zuckerberg Biohub, previously used AATI systems while at Stanford University with current Stanford professor Stephen Quake, also co-president of the CZ Biohub. Neff said in a statement that AATI's analyzers are "essential tools for our single-cell RNA-seq pipeline" and that the "sensitive qualitative analysis and accurate quantification data enable precise normalization of cell inputs before [Illumina] Nextera library construction."
AATI and Illumina have partnered since 2013 when the sequencing firm adopted Fragment Analyzer platforms in its San Diego labs, eventually placing systems in several of its labs worldwide.
Last year, AATI and Pacific Biosciences also announced a comarketing partnership to promote each other's technologies for long-read DNA sequencing; and earlier this year AATI and TTP Labtech announced a comarketing agreement for NGS library prep.